Pfizer/BioNTech: Three-dose COVID vaccine shows strong immune response in kids 6 months to 5 yrs
The trail data will be submitted to Food and Drug Administration this week, with the drugs makers hope of getting prompt, emergency-use approval
Pfizer/BioNTech said Monday their three-dose COVID-19 vaccine appears to be safe and shows a strong immune response in children ages 6 months to 5 years.
The trail data will be submitted to the Food and Drug Administration this week, with the drugs makers hoping of getting prompt, emergency-use approval.
The trails, included 1,678 children during the period in the virus' Omicron variant dominated, show about 80% efficacy, according to CNN.
In February, the FDA asked the companies to submit an emergency-use request based on two-dose data, but postponed a meeting of the agency's vaccine advisory board so the third-dose data could be considered, the wire service also reports.